**Core Concept**
Triple negative breast cancer (TNBC) is a subtype of breast cancer characterized by the absence of estrogen receptors (ER), progesterone receptors (PR), and excess HER2 protein. This lack of hormone receptors and HER2 overexpression makes TNBC more aggressive and challenging to treat.

**Why the Correct Answer is Right**
TNBC lacks the hormone receptors ER and PR, which are typically targeted by hormone therapy. Additionally, TNBC tumors often overexpress HER2, a protein that promotes cancer cell growth. The absence of ER, PR, and HER2 negativity makes TNBC a distinct clinical entity. The HER2 status in TNBC is often evaluated using immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH).

**Why Each Wrong Option is Incorrect**
**Option A:** This option is incorrect as it does not specify whether the breast cancer is triple negative or not. Without additional information, it is difficult to determine if this option is correct or not.

**Option B:** This option is incorrect as it does not specify the receptor status of the breast cancer. While some breast cancers may be hormone receptor-positive or HER2-positive, this option does not provide enough information to confirm triple negativity.

**Option C:** This option is incorrect as it does not specify the receptor status of the breast cancer. Without additional information, it is difficult to determine if this option is correct or not.

**Option D:** This option is correct as it refers to a subtype of breast cancer characterized by the absence of estrogen receptors (ER), progesterone receptors (PR), and excess HER2 protein. This makes it a triple negative breast cancer.

**Clinical Pearl / High-Yield Fact**
TNBC tends to occur in younger women and is often associated with a higher risk of recurrence and metastasis. The absence of hormone receptors and HER2 overexpression makes TNBC more challenging to treat, and treatment options often involve chemotherapy and targeted therapies.

**Correct Answer:** D.